

PKI-166

## Chemical Properties

CAS No.:	187724-61-4
Formula:	C <sub>20</sub> H <sub>18</sub> N <sub>4</sub> O
Molecular Weight:	330.38
Appearance:	N/A
Storage:	0-4°C for short term (days to weeks), or -20°C for long term (months).

## Biological Description

Description	PKI-166 is an effective and selective EGFR tyrosine kinase inhibitor (IC <sub>50</sub> : 0.7 nM).
Targets(IC <sub>50</sub> )	EGFR tyrosine kinase: 0.7 nM
In vitro	PKI-166 (0–0.5 μM; 1 hour) pretreatment suppresses EGFR autophosphorylation in human pancreatic cancer cells. PKI-166 (0.03 μM; 6 days) increased the cytotoxicity mediated by gemcitabine[1].
In vivo	PKI-166 (100 mg/kg; p.o.; daily; day 7-day 35 after xenograft) suppresses the growth of pancreatic cancer [1].

## Solubility Information

Solubility	< 1 mg/ml refers to the product slightly soluble or insoluble
------------	---

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.027 mL	15.134 mL	30.268 mL
5 mM	0.605 mL	3.027 mL	6.054 mL
10 mM	0.303 mL	1.513 mL	3.027 mL
50 mM	0.061 mL	0.303 mL	0.605 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

### Reference

1. Bruns CJ, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000 Jun 1;60(11):2926-35.

Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:[info@targetmol.com](mailto:info@targetmol.com)

Address:36 Washington Street,Wellesley Hills,MA 02481